Metsera Inc.

NASDAQ: MTSR · Real-Time Price · USD
22.91
3.10 (15.65%)
At close: Apr 29, 2025, 11:22 AM
15.65%
Bid 22.79
Market Cap 2.41B
Revenue (ttm) n/a
Net Income (ttm) -64.74M
EPS (ttm) -2.03
PE Ratio (ttm) -11.29
Forward PE n/a
Analyst Buy
Ask 22.95
Volume 380,772
Avg. Volume (20D) 936,343
Open 20.47
Previous Close 19.81
Day's Range 20.40 - 22.91
52-Week Range 12.30 - 32.81
Beta 0.00

About MTSR

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New Y...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2025
Employees 74
Stock Exchange NASDAQ
Ticker Symbol MTSR
Full Company Profile

Advertisement

Analyst Forecast

According to 4 analyst ratings, the average rating for MTSR stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 105.15% from the latest price.

Stock Forecasts
2 weeks ago
+29.86%
Metsera shares are trading higher after Pfizer dis... Unlock content with Pro Subscription